Cited by 54Blood Coagulation and Thrombosis MechanismsAtherosclerosis and Cardiovascular DiseasesInflammatory Biomarkers in Disease Prognosis

Inflammation and thrombosis – testing the hypothesis with anti- inflammatory drug trials

Open access
D’Ugo, Emilia, Libby, Peter, De Caterina, Raffaele·2016·Thrombosis and Haemostasis

Abstract

Summary: The hypothesis of atherosclerosis as an inflammatory process has been a leitmotiv in cardiology for the past 20 years, and has now led to the launch of clinical trials aimed at testing whether drugs that primarily target inflammation can reduce cardiovascular events. Inflammation indeed drives all phases of atherosclerosis, from inception, through progression, and ultimately acute thrombotic complications (plaque rupture and probably plaque erosion). Since plaque rupture and erosion cause most acute coronary syndromes, appropriately tuned anti-inflammatory treatments should limit myocardial infarction and cardiovascular death. Beyond interrupting inflammation-related plaque disruption, such treatments might, however, also ameliorate the propensity to thrombosis once the trigger (plaque rupture or erosion) has occurred. Several lines of evidence support this view: experimental data document the role of inflammation in platelet activation, tissue factor-mediated coagulation, hyperfibrinogenaemia, impaired activity of natural anticoagulants (including those expressed by endothelial cells), and reduced fibrinolytic activity. Supporting evidence also derives from the involvement of inflammation in venous thrombosis, a process that commonly occurs in the absence of traditional risk factors for atherosclerosis but is associated with several inflammatory diseases including obesity. Ongoing trials, in addition to evaluating effects on primary outcomes, will afford the opportunity to probe the possibility that anti-inflammatory interventions that yield salutary changes in biomarkers of the thrombotic/fibrinolytic balance also translate into reduction of clinical events.

Integrity signals

Registry

Crossref · 10.1160/th16-03-0246

Cites

98 of 98 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Innate and adaptive immune activation drives atherogenesis from early endothelial dysfunction to acute thrombotic complications.

    “Activation of both innate and adaptive immunity actively contributes to the initiation and progression of atherogenesis, from early endothelial dysfunction to the development of acute thrombotic complications”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
D’Ugo, E., Libby, P., & De Caterina, R.
Affiliations
  • University of Chieti-Pescara (IT)
  • Brigham and Women's Hospital (US)
Venue
Thrombosis and Haemostasis
Published
2016-11
Volume
116
Issue
12
Pages
1012-1021
ISSN
  • 0340-6245 (ISSN-L)
  • 2567-689X
OpenAlex
W2517751539
Cited by
54
References
98
Citations by year
2025: 4 · 2024: 7 · 2023: 4 · 2022: 9 · 2021: 10 · 2020: 3 · 2019: 5 · 2018: 7 · 2017: 4 · 2016: 1
FWCI
0.80
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Thrombosis and Haemostasis (publishedVersion)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
  • Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
Keywords
inflammation, thrombosis, atherosclerosis, anti-inflammatory agents, plaque rupture, plaque erosion, acute coronary syndrome, platelet activation, tissue factor, hyperfibrinogenemia, natural anticoagulants, fibrinolysis, venous thrombosis, obesity, cardiovascular events, clinical trials
MeSH terms
Anti-Inflammatory Agents, Humans, Inflammation, Thrombosis, Atherosclerosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review